Emerging mupirocin resistance in methiciüin-resistant Staphylococcus aureus isolates at a tertiary care children's hospital in Argentina.

Autor: Vázquez NM; Laboratorio de Farmacología de Activos Vegetales, Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y de Diagnóstico (CEBBAD), CONICET, carreras de Farmacia y Bioquímica. Universidad Maimónides., Cáceres Guidó P; Grupo de Medicina Integradora. Hospital de Pediatría Garrahan, Ciudad Autónoma de Buenos Aires, Argentina., Fiorilli G; Servicio de Microbiología. Hospital de Pediatría Garrahan. Ciudad Autónoma de Buenos Aires, Argentina., Moreno S; Laboratorio de Farmacología de Activos Vegetales, Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y de Diagnóstico (CEBBAD), CONICET, carreras de Farmacia y Bioquímica. Universidad Maimónides. smorenocontar@gmail.com.
Jazyk: English; Spanish; Castilian
Zdroj: Archivos argentinos de pediatria [Arch Argent Pediatr] 2019 Feb 01; Vol. 117 (1), pp. 48-51.
DOI: 10.5546/aap.2019.eng.48
Abstrakt: In Latin America, few studies have been done in mupirocin resistance and biofilm formation in methicillin-resistant Staphylococcus aureus (MRSA). This study investigated mupirocin-resistance in MRSA isolates from pediatric patients with bacteremia and their ability to form biofilm. Antibiotic resistance was analyzed with the Kirby-Bauer test and the broth microdilution method. Bacterial biofilm formation was measured using the crystal violet assay. Among MRSA isolates, 2.3 % (5/217) exhibited a high level of mupirocin-resistance with a minimum inhibitory concentration of >512 μg/mL, in addition to cross-resistance with clindamycin, erythromycin, gentamicin, and ciprofloxacin. Remarkably, biofilm formation in such isolates was moderate to high. This is the first report published in Argentina on clinical isolates of mupirocin-resistant MRSA and it is critical for following its evolution over time at a local level and in the Latin American region.
(Sociedad Argentina de Pediatría.)
Databáze: MEDLINE